» Articles » PMID: 37594082

NQO1 Drives Glioblastoma Cell Aggressiveness Through EMT Induction Via the PI3K/Akt/mTOR/Snail Pathway

Overview
Journal Int J Oncol
Specialty Oncology
Date 2023 Aug 18
PMID 37594082
Authors
Affiliations
Soon will be listed here.
Abstract

Glioblastoma multiforme (GBM) is the most frequent and lethal cancer derived from the central nervous system, of which the mesenchymal (MES) subtype seriously influences the survival and prognosis of patients. NAD(P)H: quinone acceptor oxidoreductase 1 (NQO1) serves an important role in the carcinogenesis and progression of various types of cancer; however, the specific mechanism underlying the regulatory effects of NQO1 on GBM is unclear. Thus, the present study aimed to explore the role and mechanism of NQO1 in GBM progression. The results of bioinformatics analysis and immunohistochemistry showed that high expression of NQO1 was significantly related to the MES phenotype of GBM and shorter survival. In addition, MTT, colony formation, immunofluorescence and western blot analyses, and lung metastasis model experiments suggested that silencing NQO1 inhibited the proliferation and metastasis of GBM cells and . Furthermore, western blotting showed that the activity of the PI3K/Akt/mTOR signaling pathway was revealed to be inhibited by downregulation of NQO1 expression, whereas it was enhanced by overexpression of NQO1. Notably, co‑immunoprecipitation and ubiquitination experiments suggested that Snail was considered an important downstream target of NQO1 in GBM cells. Snail knockdown could eliminate the promoting effect of ectopic NQO1 on the proliferation and invasion of GBM cells, and reduce its effects on the activity of PI3K/Akt/mTOR signaling pathway. These results indicated that NQO1 could promote GBM aggressiveness by activating the PI3K/Akt/mTOR signaling pathway in a Snail‑dependent manner, and NQO1 and its relevant pathways may be considered novel targets for GBM therapy.

Citing Articles

Fructose 1,6-bisphosphatase 1 is a potential biomarker affecting the malignant phenotype and aerobic glycolysis in glioblastoma.

Lu W, Huang G, Yu Y, Zhai X, Zhou X PeerJ. 2025; 13:e18926.

PMID: 39902328 PMC: 11789649. DOI: 10.7717/peerj.18926.


Targeted delivery of napabucasin with radiotherapy improves outcomes in diffuse midline glioma.

Gallitto M, Zhang X, De Los Santos G, Wei H, Fernandez E, Duan S Neuro Oncol. 2024; 27(3):795-810.

PMID: 39394920 PMC: 11889722. DOI: 10.1093/neuonc/noae215.


Apoptotic vesicles (apoVs) derived from fibroblast-converted hepatocyte-like cells effectively ameliorate liver fibrosis.

Zhong Z, Cui X, Tan K, Wu X, Zhu X, Zhang J J Nanobiotechnology. 2024; 22(1):541.

PMID: 39238002 PMC: 11375929. DOI: 10.1186/s12951-024-02824-7.


SLC7A11 promotes EMT and metastasis in invasive pituitary neuroendocrine tumors by activating the PI3K/AKT signaling pathway.

Gui S, Yu W, Xie J, Peng L, Xiong Y, Song Z Endocr Connect. 2024; 13(7).

PMID: 38722255 PMC: 11227052. DOI: 10.1530/EC-24-0097.

References
1.
Tang G, Luo L, Zhang J, Zhai D, Huang D, Yin J . lncRNA LINC01057 promotes mesenchymal differentiation by activating NF-κB signaling in glioblastoma. Cancer Lett. 2020; 498:152-164. DOI: 10.1016/j.canlet.2020.10.047. View

2.
Wang X, Liu Y, Han A, Tang C, Xu R, Feng L . The NQO1/p53/SREBP1 axis promotes hepatocellular carcinoma progression and metastasis by regulating Snail stability. Oncogene. 2022; 41(47):5107-5120. DOI: 10.1038/s41388-022-02477-6. View

3.
Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M . Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110. PMC: 2818769. DOI: 10.1016/j.ccr.2009.12.020. View

4.
Ernster L, Lindberg O . Animal mitochondria. Annu Rev Physiol. 1958; 20:13-42. DOI: 10.1146/annurev.ph.20.030158.000305. View

5.
Courtney K, Corcoran R, Engelman J . The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010; 28(6):1075-83. PMC: 2834432. DOI: 10.1200/JCO.2009.25.3641. View